Most prostate cancers missed by raising the upper limit of normal prostate-specific antigen for men in their sixties are clinically significant.
about
The value of current diagnostic tests in prostate cancer screening.New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer.Transperineal extended biopsy improves the clinically significant prostate cancer detection rate: a comparative study of 6 and 12 biopsy cores.Development and external validation of a nomogram for predicting cancer probability at initial prostate biopsy using the life expectancy- and prostate volume-adjusted biopsy scheme.Allelic variability in PSA & AR genes: a novel biomarker on the horizon for carcinoma prostate.
P2860
Most prostate cancers missed by raising the upper limit of normal prostate-specific antigen for men in their sixties are clinically significant.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Most prostate cancers missed b ...... es are clinically significant.
@en
Most prostate cancers missed b ...... es are clinically significant.
@nl
type
label
Most prostate cancers missed b ...... es are clinically significant.
@en
Most prostate cancers missed b ...... es are clinically significant.
@nl
prefLabel
Most prostate cancers missed b ...... es are clinically significant.
@en
Most prostate cancers missed b ...... es are clinically significant.
@nl
P2093
P1433
P1476
Most prostate cancers missed b ...... ies are clinically significant
@en
P2093
G J O'Dowd
I C Bassler
T A Stamey
T J Bassler
P304
P356
10.1016/S0090-4295(98)00366-5
P407
P577
1998-12-01T00:00:00Z